Global Neuraminidase Inhibitors Drug Market Growth (Status and Outlook) 2022-2028
- LP 4890923
- 60 Pages
- March 2022
- Pharmaceuticals
The United States Neuraminidase Inhibitors Drug market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Neuraminidase Inhibitors Drug market, reaching US$ million by the year 2028. As for the Europe Neuraminidase Inhibitors Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Neuraminidase Inhibitors Drug players cover Roche, GSK, Gilead Sciences, and Daiichi Sankyo, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Neuraminidase Inhibitors Drug market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Oseltamivir
Zanamivir
Peramivir
Laninamivir
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Roche
GSK
Gilead Sciences
Daiichi Sankyo
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neuraminidase Inhibitors Drug Market Size 2017-2028
2.1.2 Neuraminidase Inhibitors Drug Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Neuraminidase Inhibitors Drug Segment by Type
2.2.1 Oseltamivir
2.2.2 Zanamivir
2.2.3 Peramivir
2.2.4 Laninamivir
2.3 Neuraminidase Inhibitors Drug Market Size by Type
2.3.1 Neuraminidase Inhibitors Drug Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Neuraminidase Inhibitors Drug Market Size Market Share by Type (2017-2022)
2.4 Neuraminidase Inhibitors Drug Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.4.4 Others
2.5 Neuraminidase Inhibitors Drug Market Size by Application
2.5.1 Neuraminidase Inhibitors Drug Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Neuraminidase Inhibitors Drug Market Size Market Share by Application (2017-2022)
3 Neuraminidase Inhibitors Drug Market Size by Player
3.1 Neuraminidase Inhibitors Drug Market Size Market Share by Players
3.1.1 Global Neuraminidase Inhibitors Drug Revenue by Players (2020-2022)
3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2020-2022)
3.2 Global Neuraminidase Inhibitors Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Neuraminidase Inhibitors Drug by Regions
4.1 Neuraminidase Inhibitors Drug Market Size by Regions (2017-2022)
4.2 Americas Neuraminidase Inhibitors Drug Market Size Growth (2017-2022)
4.3 APAC Neuraminidase Inhibitors Drug Market Size Growth (2017-2022)
4.4 Europe Neuraminidase Inhibitors Drug Market Size Growth (2017-2022)
4.5 Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth (2017-2022)
5 Americas
5.1 Americas Neuraminidase Inhibitors Drug Market Size by Country (2017-2022)
5.2 Americas Neuraminidase Inhibitors Drug Market Size by Type (2017-2022)
5.3 Americas Neuraminidase Inhibitors Drug Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuraminidase Inhibitors Drug Market Size by Region (2017-2022)
6.2 APAC Neuraminidase Inhibitors Drug Market Size by Type (2017-2022)
6.3 APAC Neuraminidase Inhibitors Drug Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Neuraminidase Inhibitors Drug by Country (2017-2022)
7.2 Europe Neuraminidase Inhibitors Drug Market Size by Type (2017-2022)
7.3 Europe Neuraminidase Inhibitors Drug Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neuraminidase Inhibitors Drug by Region (2017-2022)
8.2 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2017-2022)
8.3 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Neuraminidase Inhibitors Drug Market Forecast
10.1 Global Neuraminidase Inhibitors Drug Forecast by Regions (2023-2028)
10.1.1 Global Neuraminidase Inhibitors Drug Forecast by Regions (2023-2028)
10.1.2 Americas Neuraminidase Inhibitors Drug Forecast
10.1.3 APAC Neuraminidase Inhibitors Drug Forecast
10.1.4 Europe Neuraminidase Inhibitors Drug Forecast
10.1.5 Middle East & Africa Neuraminidase Inhibitors Drug Forecast
10.2 Americas Neuraminidase Inhibitors Drug Forecast by Country (2023-2028)
10.2.1 United States Neuraminidase Inhibitors Drug Market Forecast
10.2.2 Canada Neuraminidase Inhibitors Drug Market Forecast
10.2.3 Mexico Neuraminidase Inhibitors Drug Market Forecast
10.2.4 Brazil Neuraminidase Inhibitors Drug Market Forecast
10.3 APAC Neuraminidase Inhibitors Drug Forecast by Region (2023-2028)
10.3.1 China Neuraminidase Inhibitors Drug Market Forecast
10.3.2 Japan Neuraminidase Inhibitors Drug Market Forecast
10.3.3 Korea Neuraminidase Inhibitors Drug Market Forecast
10.3.4 Southeast Asia Neuraminidase Inhibitors Drug Market Forecast
10.3.5 India Neuraminidase Inhibitors Drug Market Forecast
10.3.6 Australia Neuraminidase Inhibitors Drug Market Forecast
10.4 Europe Neuraminidase Inhibitors Drug Forecast by Country (2023-2028)
10.4.1 Germany Neuraminidase Inhibitors Drug Market Forecast
10.4.2 France Neuraminidase Inhibitors Drug Market Forecast
10.4.3 UK Neuraminidase Inhibitors Drug Market Forecast
10.4.4 Italy Neuraminidase Inhibitors Drug Market Forecast
10.4.5 Russia Neuraminidase Inhibitors Drug Market Forecast
10.5 Middle East & Africa Neuraminidase Inhibitors Drug Forecast by Region (2023-2028)
10.5.1 Egypt Neuraminidase Inhibitors Drug Market Forecast
10.5.2 South Africa Neuraminidase Inhibitors Drug Market Forecast
10.5.3 Israel Neuraminidase Inhibitors Drug Market Forecast
10.5.4 Turkey Neuraminidase Inhibitors Drug Market Forecast
10.5.5 GCC Countries Neuraminidase Inhibitors Drug Market Forecast
10.6 Global Neuraminidase Inhibitors Drug Forecast by Type (2023-2028)
10.7 Global Neuraminidase Inhibitors Drug Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Neuraminidase Inhibitors Drug Product Offered
11.1.3 Roche Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Neuraminidase Inhibitors Drug Product Offered
11.2.3 GSK Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 GSK Main Business Overview
11.2.5 GSK Latest Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Information
11.3.2 Gilead Sciences Neuraminidase Inhibitors Drug Product Offered
11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Gilead Sciences Main Business Overview
11.3.5 Gilead Sciences Latest Developments
11.4 Daiichi Sankyo
11.4.1 Daiichi Sankyo Company Information
11.4.2 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Offered
11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Daiichi Sankyo Main Business Overview
11.4.5 Daiichi Sankyo Latest Developments
12 Research Findings and Conclusion
Table 1. Neuraminidase Inhibitors Drug Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Oseltamivir
Table 3. Major Players of Zanamivir
Table 4. Major Players of Peramivir
Table 5. Major Players of Laninamivir
Table 6. Neuraminidase Inhibitors Drug Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 7. Global Neuraminidase Inhibitors Drug Market Size by Type (2017-2022) & ($ Millions)
Table 8. Global Neuraminidase Inhibitors Drug Market Size Market Share by Type (2017-2022)
Table 9. Neuraminidase Inhibitors Drug Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 10. Global Neuraminidase Inhibitors Drug Market Size by Application (2017-2022) & ($ Millions)
Table 11. Global Neuraminidase Inhibitors Drug Market Size Market Share by Application (2017-2022)
Table 12. Global Neuraminidase Inhibitors Drug Revenue by Players (2020-2022) & ($ Millions)
Table 13. Global Neuraminidase Inhibitors Drug Revenue Market Share by Player (2020-2022)
Table 14. Neuraminidase Inhibitors Drug Key Players Head office and Products Offered
Table 15. Neuraminidase Inhibitors Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Neuraminidase Inhibitors Drug Market Size by Regions 2017-2022 & ($ Millions)
Table 19. Global Neuraminidase Inhibitors Drug Market Size Market Share by Regions (2017-2022)
Table 20. Americas Neuraminidase Inhibitors Drug Market Size by Country (2017-2022) & ($ Millions)
Table 21. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Country (2017-2022)
Table 22. Americas Neuraminidase Inhibitors Drug Market Size by Type (2017-2022) & ($ Millions)
Table 23. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Type (2017-2022)
Table 24. Americas Neuraminidase Inhibitors Drug Market Size by Application (2017-2022) & ($ Millions)
Table 25. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Application (2017-2022)
Table 26. APAC Neuraminidase Inhibitors Drug Market Size by Region (2017-2022) & ($ Millions)
Table 27. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Region (2017-2022)
Table 28. APAC Neuraminidase Inhibitors Drug Market Size by Type (2017-2022) & ($ Millions)
Table 29. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Type (2017-2022)
Table 30. APAC Neuraminidase Inhibitors Drug Market Size by Application (2017-2022) & ($ Millions)
Table 31. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Application (2017-2022)
Table 32. Europe Neuraminidase Inhibitors Drug Market Size by Country (2017-2022) & ($ Millions)
Table 33. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Country (2017-2022)
Table 34. Europe Neuraminidase Inhibitors Drug Market Size by Type (2017-2022) & ($ Millions)
Table 35. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Type (2017-2022)
Table 36. Europe Neuraminidase Inhibitors Drug Market Size by Application (2017-2022) & ($ Millions)
Table 37. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Application (2017-2022)
Table 38. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Region (2017-2022) & ($ Millions)
Table 39. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Region (2017-2022)
Table 40. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Type (2017-2022) & ($ Millions)
Table 41. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Type (2017-2022)
Table 42. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Application (2017-2022) & ($ Millions)
Table 43. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Application (2017-2022)
Table 44. Key Market Drivers & Growth Opportunities of Neuraminidase Inhibitors Drug
Table 45. Key Market Challenges & Risks of Neuraminidase Inhibitors Drug
Table 46. Key Industry Trends of Neuraminidase Inhibitors Drug
Table 47. Global Neuraminidase Inhibitors Drug Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 48. Global Neuraminidase Inhibitors Drug Market Size Market Share Forecast by Regions (2023-2028)
Table 49. Global Neuraminidase Inhibitors Drug Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 50. Global Neuraminidase Inhibitors Drug Market Size Market Share Forecast by Type (2023-2028)
Table 51. Global Neuraminidase Inhibitors Drug Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 52. Global Neuraminidase Inhibitors Drug Market Size Market Share Forecast by Application (2023-2028)
Table 53. Roche Details, Company Type, Neuraminidase Inhibitors Drug Area Served and Its Competitors
Table 54. Roche Neuraminidase Inhibitors Drug Product Offered
Table 55. Roche Neuraminidase Inhibitors Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 56. Roche Main Business
Table 57. Roche Latest Developments
Table 58. GSK Details, Company Type, Neuraminidase Inhibitors Drug Area Served and Its Competitors
Table 59. GSK Neuraminidase Inhibitors Drug Product Offered
Table 60. GSK Main Business
Table 61. GSK Neuraminidase Inhibitors Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 62. GSK Latest Developments
Table 63. Gilead Sciences Details, Company Type, Neuraminidase Inhibitors Drug Area Served and Its Competitors
Table 64. Gilead Sciences Neuraminidase Inhibitors Drug Product Offered
Table 65. Gilead Sciences Main Business
Table 66. Gilead Sciences Neuraminidase Inhibitors Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 67. Gilead Sciences Latest Developments
Table 68. Daiichi Sankyo Details, Company Type, Neuraminidase Inhibitors Drug Area Served and Its Competitors
Table 69. Daiichi Sankyo Neuraminidase Inhibitors Drug Product Offered
Table 70. Daiichi Sankyo Main Business
Table 71. Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 72. Daiichi Sankyo Latest Developments
List of Figures
Figure 1. Neuraminidase Inhibitors Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Neuraminidase Inhibitors Drug Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Neuraminidase Inhibitors Drug Market Size Market Share by Type in 2021
Figure 7. Neuraminidase Inhibitors Drug in Hospital Pharmacy
Figure 8. Global Neuraminidase Inhibitors Drug Market: Hospital Pharmacy (2017-2022) & ($ Millions)
Figure 9. Neuraminidase Inhibitors Drug in Retail Pharmacy
Figure 10. Global Neuraminidase Inhibitors Drug Market: Retail Pharmacy (2017-2022) & ($ Millions)
Figure 11. Neuraminidase Inhibitors Drug in Online Pharmacy
Figure 12. Global Neuraminidase Inhibitors Drug Market: Online Pharmacy (2017-2022) & ($ Millions)
Figure 13. Neuraminidase Inhibitors Drug in Others
Figure 14. Global Neuraminidase Inhibitors Drug Market: Others (2017-2022) & ($ Millions)
Figure 15. Global Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2021
Figure 16. Global Neuraminidase Inhibitors Drug Revenue Market Share by Player in 2021
Figure 17. Global Neuraminidase Inhibitors Drug Market Size Market Share by Regions (2017-2022)
Figure 18. Americas Neuraminidase Inhibitors Drug Market Size 2017-2022 ($ Millions)
Figure 19. APAC Neuraminidase Inhibitors Drug Market Size 2017-2022 ($ Millions)
Figure 20. Europe Neuraminidase Inhibitors Drug Market Size 2017-2022 ($ Millions)
Figure 21. Middle East & Africa Neuraminidase Inhibitors Drug Market Size 2017-2022 ($ Millions)
Figure 22. Americas Neuraminidase Inhibitors Drug Value Market Share by Country in 2021
Figure 23. Americas Neuraminidase Inhibitors Drug Consumption Market Share by Type in 2021
Figure 24. Americas Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2021
Figure 25. United States Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 26. Canada Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 27. Mexico Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 28. Brazil Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 29. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Region in 2021
Figure 30. APAC Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2021
Figure 31. China Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 32. Japan Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 33. Korea Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 34. Southeast Asia Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 35. India Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 36. Australia Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 37. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Country in 2021
Figure 38. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Type in 2021
Figure 39. Europe Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2021
Figure 40. Germany Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 41. France Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 42. UK Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 43. Italy Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 44. Russia Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 45. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Region in 2021
Figure 46. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Type in 2021
Figure 47. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Market Share by Application in 2021
Figure 48. Egypt Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 49. South Africa Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 50. Israel Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 51. Turkey Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 52. GCC Country Neuraminidase Inhibitors Drug Market Size Growth 2017-2022 ($ Millions)
Figure 53. Americas Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 54. APAC Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 55. Europe Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 56. Middle East & Africa Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 57. United States Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 58. Canada Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 59. Mexico Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 60. Brazil Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 61. China Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 62. Japan Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 63. Korea Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 64. Southeast Asia Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 65. India Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 66. Australia Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 67. Germany Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 68. France Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 69. UK Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 70. Italy Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 71. Russia Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 72. Spain Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 73. Egypt Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 74. South Africa Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 75. Israel Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 76. Turkey Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Figure 77. GCC Countries Neuraminidase Inhibitors Drug Market Size 2023-2028 ($ Millions)
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
